<DOC>
	<DOCNO>NCT00612898</DOCNO>
	<brief_summary>Apricitabine new NRTI active drug-resistant HIV . NRTIs often include part patient ' treatment , many HIV-infected patient develop resistance commonly use NRTIs lamivudine ( 3TC ) emtricitabine ( FTC ) . This study examine whether include apricitabine part patient ' treatment effective include lamivudine , patient change treatment drug resistance .</brief_summary>
	<brief_title>Study Efficacy Safety Apricitabine , New NRTI , Treat Drug-resistant HIV Infection</brief_title>
	<detailed_description>ATC potent antiviral activity vitro ( wild-type HIV-1 HIV-1 mutation reverse transcriptase confer resistance NRTIs ) , clinical study treatment-na√Øve treatment-experienced patient M184V , include presence additional NRTI mutation reverse transcriptase . The M184V mutation commonly present amongst patient fail regimen contain either two deoxycytidine analog lamivudine emtricitabine . Whilst lamivudine therapy often maintain patient harbor M184V mutation setting , deoxycytidine analog currently available effectively suppress replication HIV-1 containing M184V/I mutation , particularly presence additional NRTI mutation . The purpose study extend efficacy safety establish study AVX-201 ATC patient HIV-1 infect fail treatment lamivudine emtricitabine confirm M184V/I mutation . Patients enrol fail current lamivudine- emtricitabine-containing regimen therefore limit remain NRTI treatment option . This study investigate whether possible improve control HIV-1 viral replication include ATC within treatment experience patient 's new optimize background regimen follow ART treatment failure .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>HIV1 positive M184V/I mutation reverse transcriptase ; 18 year age old ; Currently take lamivudine ( 3TC ) emtricitabine ( FTC ) Female patient pregnant breastfeeding ; Current hepatitis B virus ( HBV ) infection ; Current treatment hepatitis C virus infection ; Renal function adequate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>HIV infection</keyword>
	<keyword>Drug resistance</keyword>
	<keyword>Reverse transcriptase inhibitor</keyword>
	<keyword>Nucleoside analogue</keyword>
	<keyword>treatment experience</keyword>
</DOC>